Skip to content
TrialScanner

NCT03745287

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Phase 2/Phase 3CompletedVRTXLeadCRSPCollaborator

Registry record

Lead sponsor
Vertex Pharmaceuticals Incorporated
Conditions
Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies
Primary completion
Jul 7, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03745287 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03745287: A Safety and Efficacy Study... | TrialScanner